TGTX TG Therapeutics Inc

$TGTX A $1B global revenue target less than four years after BRIUMVI launched. That's a commercial story, not just biotech hope.

$TGTX It looks like we've done it, and we have an investment that not only helps us financially, but also people suffering from this disease. It makes me quite proud, and I hope this is just the beginning 😁

$TGTX if you're a BP trying to replace $2B-$4B in loss revenues in the next couple of years, TGTX is your best candidate.

$TGTX Wow, a real effort out in the media today to miss report these results. These bots never look past the other headlines. The missed EPS number are a joke. Third quarter 2025 results was an adjusted number that included a non-recurring income tax benefit of approximately $365MM caused by the release of their deferred tax asset valuation allowance. Acutal EPS did not miss. There are other headlines out that saying they missed some numbers. The numbers they missed are analyst driven, and were wrong. Compare the ACTUAL number and it is a different story. Shorts are trying hard to derail this run. Don't fall for it. Dig deeper and get the REAL story.

$TGTX Mike - lots of haters a few years back. So glad I tuned them out and kept an eye on the future! Nice work!

$TGTX I think Monday will be an inflection point for this stock and will be very positive 

$TGTX Held $60+ I'll take that. Consolidating here the rest of this event-filled week would be a win. Let's get past election ripples and on to Monday morning!

$TGTX Looking at the total revenues, TG has achieved its run rate of $1B in Q3! Earlier in the year, I thought it would happen in Q3 or Q4, as the months rolled on, I was leaning towards Q4, but this is great! Q4 numbers will exceed Q3's, lookout.

$TGTX Update on US' antiCD20 MS market in 2026. Market to exceed $10B this year and $15B by 2030. Briumvi aggressively gaining market share from Ocrevus. Trend is very clear that Briumvi peak sales (Subq included) in US will be north of $5B.

$TGTX since Q3 is always seasonally slow due to summer, I feel Q4 may cross 250M alone for 1B+ USA alone on forward basis.

$TGTX have a good weekend longs. If they do cook us on Monday all we be good at JPM January anyway. It’s all noise until subq is released.

$TGTX Breaking News: Alec of BoA raises price target to $21.01 but reiterates sell so they can buy up your shares.😂

$TGTX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $0.35 down -85.60% YoY • Reported revenue of $259.94M up 60.74% YoY • TG Therapeutics raised full-year 2026 total global revenue guidance to approximately $1B and BRIUMVI U.S. net product revenue guidance to approximately $915.92B; operating expense guidance remains approximately $450.5B, excluding non-cash compensation.

$TGTX Guys forget 2027 we are going to be billion $$ earner this year only 4byr from launch

$TGTX TG has become one of my "boring" stocks. I'll miss the highs and lows of FDA approvals, scary CCs, competition. B IV + SUBQ will dominate the space. Whatever happens in the short term means nothing. Monday will be fun, but all is good in TG land.

$TGTX looks like those unusual options calls are going to start ringing the regester. Interesting.

$TGTX if no sub-q data Monday, he will at least tell it will be by year end considering trial is over. Mike never sold a single of his 14M+ shares

$TGTX A $100M buyback in one quarter? That's a much louder vote of confidence than another CEO interview.

$TGTX anyone here living in Morrisville North Carolina, who could pop along to the head office and have a look in the reception visitors book? See if any potential buyers have been visiting?

$TGTX $IBB $XBI JPM conference will go crazy. 2026 revenue guidance is 1B Quarterly Breakdown (2026) Q1 2026 Total Revenue: $204.9 million Q2 2026 Total Revenue: $240.3 million Q3 2026 Total Revenue: $259.9 million Q4 2026 will be at least 295M to hit that 1B guidance. Cumulative 9-Month Total: $705.2 million With $705.2 million banked through September, the company only needs roughly $295 million in Q4 to hit its newly raised full-year guidance of ~$1.0 billion. Sub-Q data will put this to triple digit.